Medication Guide App

WPI 900 (Glipizide extended release 2.5 mg)

Pill imprint WPI 900 has been identified as Glipizide extended release 2.5 mg.

Glipizide is used in the treatment of diabetes, type 2 and belongs to the drug class sulfonylureas. Risk cannot be ruled out during pregnancy. Glipizide 2.5 mg is not subject to the Controlled Substances Act.

See also related documents.

Imprint Search

Images for WPI 900

Glipizide extended release 2.5 mg WPI 900
Glipizide extended release 2.5 mg WPI 900
Glipizide extended release 2.5 mg WPI 900
Glipizide extended release
Imprint:
WPI 900
Strength:
2.5 mg
Color:
Yellow
Shape:
Round
Availability:
Prescription only
Drug Class:
Sulfonylureas
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
N - Not a controlled drug
Manufacturer:
Watson Pharmaceuticals
National Drug Code (NDC):
00591-0900
Inactive Ingredients:
acetyltributyl citrate
hydroxyethyl cellulose (2000 mpa.s at 1%)
hydroxypropyl cellulose (type h)
lactose monohydrate
magnesium stearate
methacrylic acid - methyl methacrylate copolymer (1:1)
polyethylene glycol
FD&C Yellow No. 6
shellac
isopropyl alcohol
ferrosoferric oxide
butyl alcohol
propylene glycol
ammonia
Other Manufacturers / Repackagers:
NDC CodeManufacturer / Repackager
00228-2898 Actavis (acquired Watson & Warner Chilcott)
68084-0295 Amerisource Health Services

Note: Inactive ingredients may vary.

View Details Print Page

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2014 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide
(web3)